Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients at GINA steps 4 and 5. Recently, RCTs proved the efficacy and safety of fixed triple combinations of moderate and high dose of ICS and LABA, LAMA in a very selected asthmatic population, resulting in the market authorisation of these products. However, there is a lack of evidence on the real-world effectiveness of these therapies, especially with regards to improvement in symptom scores and adherence.
Sponsor: Chiesi Slovenija, d.o.o.
You may qualify if…
- ✓ Physician-confirmed clinical diagnosis of asthma according to GINA guidelines and treated for at least 3 years before inclusion
- ✓ Patients ≥ 18 years of age in ambulatory care
- ✓ Uncontrolled asthma according to the physician's clinical assessment despite the use of:
- ✓ 1. LABA and high dose ICS or
- ✓ 2. LABA and high-dose ICS + LAMA multi-inhaler triple therapy for a minimum of three months.
- ✓ Patients who are eligible for the use of Trimbow 172/5/9 μg pMDI according to the SmPC :
- ✓ 1. at least on exacerbation, requiring systemic (oral or intravenous) corticosteroids in the previous 12 months
- ✓ 2. uncontrolled asthma (ACT≤15) or partially controlled asthma (15\<ACT\<20)
You may not qualify if…
- ✕ Participation in any clinical trial within 30 days prior to enrolment
- ✕ Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment
- ✕ Another respiratory condition, apart from asthma or COPD, that may interfere with the effectiveness of the treatment studied AND/OR another important clinical situation that may interfere with patient's compliance with the treatment.
- ✕ Continuous use of oral (\>5 mg prednisolone/day OR \>4 mg methylprednisolone/day) OR intravenous corticosteroids
- ✕ Use of continuous oxygen therapy
- ✕ Any malignant disease in the last 5 years
- ✕ Tuberculosis (active or anamnestic)
- ✕ Actual or previous use of biologics for asthma treatment in the past 12 months
Source: ClinicalTrials.gov · NCT07489911 · last updated 2026-03-24